BNTX logo

BioNTech SE

BNTX
Healthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79

Analyst Consensus

Buy24 analysts
Strong Buy
0
Buy
20
Hold
4
Sell
0
Strong Sell
0
Consensus Target
$120.33
Implied Upside
+37.5%
Low Target
$96.00
High Target
$140.00

Price Target Trend

Last Month
$132.00
1 target · +51% vs price
Last Quarter
$125.40
5 targets · +43% vs price
Last Year
$131.68
19 targets · +50% vs price
All Time
$146.00
55 targets · +67% vs price

Rating Trend

Dec 25
15 buy · 5 hold · 0 sell
Jan 26
16 buy · 5 hold · 0 sell
Feb 26
16 buy · 5 hold · 0 sell
Mar 26
15 buy · 5 hold · 0 sell
Apr 26
14 buy · 5 hold · 1 sell
May 26
14 buy · 6 hold · 1 sell
Jun 26
15 buy · 5 hold · 0 sell
Jul 26
15 buy · 5 hold · 1 sell
Aug 26
15 buy · 5 hold · 1 sell
Sep 26
15 buy · 5 hold · 1 sell
Oct 26
14 buy · 7 hold · 1 sell
Nov 26
14 buy · 7 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 14, 2026Canaccord Genuity$132.00(+48%)$89.01TheFly
Oct 7, 2026Morgan StanleyTerence Flynn$114.00(+19%)$95.63TheFly
Sep 16, 2026Berenberg Bank$140.00(+45%)$96.69TheFly
Sep 8, 2026BMO CapitalEvan David Seigerman$105.00(+1%)$103.76StreetInsider
Aug 31, 2026Canaccord Genuity$136.00(+33%)$102.08TheFly
Aug 5, 2026Canaccord Genuity$142.00(+55%)$91.35TheFly
Jul 8, 2026Morgan Stanley$119.00(+26%)$94.29TheFly
May 27, 2026UBS$135.00(+46%)$92.25TheFly
May 21, 2026Bernstein$96.00(+6%)$90.93TheFly
May 6, 2026Canaccord Genuity$158.00(+65%)$95.50TheFly
Apr 10, 2026Morgan StanleyTerence Flynn$126.00(+35%)$93.38TheFly
Mar 11, 2026BMO CapitalEvan David Seigerman$128.00(+41%)$90.52StreetInsider
Mar 10, 2026JefferiesAkash Tewari$138.00(+65%)$83.89StreetInsider
Mar 10, 2026Truist FinancialAsthika Goonewardene$155.00(+85%)$83.89StreetInsider
Mar 10, 2026Morgan Stanley$128.00(+53%)$83.89StreetInsider
Feb 2, 2026Leerink Partners$113.00(-1%)$113.75TheFly
Jan 16, 2026Goldman Sachs$142.00(+34%)$106.07TheFly
Dec 11, 2025Berenberg BankHarry Gillis$155.00(+62%)$95.68TheFly
Dec 11, 2025H.C. WainwrightRaghuram Selvaraju$140.00(+44%)$96.91StreetInsider
Nov 3, 2025Morgan Stanley$134.00(+29%)$103.95TheFly

Recent Rating Actions

FirmActionRatingDate
UBSmaintainBuyNov 4, 2026
Evercore ISI GroupmaintainOutperformNov 4, 2026
Wells FargomaintainOverweightNov 4, 2026
Morgan StanleymaintainOverweightNov 4, 2026
Canaccord GenuitymaintainBuyOct 14, 2026
Morgan StanleymaintainOverweightOct 7, 2026
BMO CapitaldowngradeOutperform →Market PerformSep 8, 2026
Canaccord GenuitymaintainBuyAug 31, 2026
CitigroupmaintainBuyAug 5, 2026
Evercore ISI GroupmaintainOutperformAug 5, 2026
Morgan StanleymaintainOverweightJul 8, 2026
UBSupgradeNeutral →BuyMay 27, 2026
Canaccord GenuitymaintainBuyMay 6, 2026
Wells FargomaintainOverweightMay 6, 2026
HC Wainwright & Co.maintainBuyApr 27, 2026
Morgan StanleymaintainOverweightApr 10, 2026
HC Wainwright & Co.maintainBuyMar 31, 2026
CitigroupmaintainBuyMar 11, 2026
Morgan StanleymaintainOverweightMar 11, 2026
BMO CapitalmaintainOutperformMar 11, 2026
TD CowenmaintainHoldMar 11, 2026
Canaccord GenuitymaintainBuyMar 11, 2026
JefferiesmaintainBuyMar 10, 2026
Goldman SachsupgradeNeutral →BuyJan 16, 2026
HC Wainwright & Co.maintainBuyNov 10, 2025

Earnings History

Next report: Mar 9, 2027 · EPS est. $-1.90
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 3, 2026$0.83$0.76$1.46B$1.17B
Aug 4, 2026$-3.70$-2.40$120.6M$180.2M
May 5, 2026$-2.43$-2.54$136.4M$207.4M
Mar 10, 2026$-1.44$-0.22$1.07B$902.3M
Nov 3, 2025$-0.14$-1.12$1.78B$843.7M
Aug 4, 2025$-1.82$-2.69$307.1M$177.8M
May 5, 2025$-1.82$-2.48$200.4M$215.1M
Mar 10, 2025$1.15$0.46$1.23B$1.18B

News

Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher

A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.

Nov 6, 2026247wallst.com
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?

Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.

Nov 5, 2026fool.com
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)

BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.

Nov 4, 2026seekingalpha.com
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript

BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Divisi…

Nov 3, 2026seekingalpha.com
BioNTech Q3 Earnings Call Highlights

BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.

Nov 3, 2026marketbeat.com
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median ov…

Nov 3, 2026globenewswire.com
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.

Oct 28, 2026247wallst.com
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next

Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.

Oct 26, 2026investopedia.com
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.

Oct 26, 2026247wallst.com
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator's choice of chemotherapy in chemotherapy-naïve patie…

Oct 26, 2026globenewswire.com
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy…

Oct 25, 2026globenewswire.com
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on their face. Moderna stock is at $184.

Oct 22, 2026247wallst.com
BioNTech, Gilead to test drug combination in advanced breast cancer trial

BioNTech, Gilead to test drug combination in advanced breast cancer trial

Oct 22, 2026reuters.com
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator …

Oct 22, 2026globenewswire.com
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

Oct 20, 2026globenewswire.com
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company's tumor focus areas, including lung and breast cancer, at the European Society for Medical Oncology (“ESMO”) 2026 Congress held in Madrid, Spain, from October 23–27, 2026.

Oct 19, 2026globenewswire.com
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech needs new products to kickstart sales and earnings growth. But two of the company's candidates have experienced setbacks recently.

Oct 18, 2026fool.com
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig, BioNTech's oncology pipeline is moving well beyond early-stage research.

Oct 17, 2026fool.com
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares BioNTech and MiMedx Group's net

Oct 17, 2026defenseworld.net
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.

Oct 16, 2026247wallst.com